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Glutamine may have beneﬁts during immaturity or critical illness in early life but its eﬀects on outcome end hardpoints are
controversial. Our aim was to review randomized studies on glutamine supplementation in pups, infants, and children examining
whether glutamine aﬀects outcome. Experimental work has proposed various mechanisms of glutamine action but none of the
randomizedstudiesinearlylifeshowedanyeﬀectonmortalityandonlyafewshowedsomeeﬀectoninﬂammatoryresponse,organ
function, and a trend for infection control. Although apparently safe in animal models (pups), premature infants, and critically ill
children, glutamine supplementation does not reduce mortality or late onset sepsis, and its routine use cannot be recommended in
these sensitive populations. Large prospectively stratiﬁed trials are needed to better deﬁne the crucial interrelations of “glutamine-
heat shock proteins-stress response” in critical illness and to identify the speciﬁc subgroups of premature neonates and critically
ill infants or children who may have a greater need for glutamine and who may eventually beneﬁt from its supplementation. The
methodological problems noted in the reviewed randomized experimental and clinical trials should be seriously considered in any
future well-designed large blinded randomized controlled trial involving glutamine supplementation in critical illness.
1.Introduction
Amino acids have a crucial role in protein synthesis, trigger
signaling cascades that regulate various aspects of fuel and
energy metabolism, and serve as precursors for important
substrates. Glutamine, the most abundant amino acid in
the muscle and plasma of humans traditionally considered a
nonessential amino acid, now appears to be a conditionally
essential nutrient during stress, injury [1], or illness [2].
During the acute stress of critical illness, large amounts
of glutamine are produced by glutamine synthetase from
muscle tissue [3] in response to stress and the regulation
of glutamine synthetase protein turnover in response to
glutamine concentrations [4]. Despite this signiﬁcant release
of glutamine, plasma levels decrease signiﬁcantly following
major burns in adults and remain decreased for over 21
days [5]. This severe glutamine deﬁciency occurs rapidly
in adults and is associated with increased critical illness
morbidity and mortality [6]. Similarly, the sudden cessation
of glutamine supply from the mother to premature infants,
who are already stressed and undergoing rapid growth,
may be detrimental [7]. Thus, whereas plasma glutamine
increases during the ﬁrst days of life in breastfed infants
[8], glutamine and arginine deﬁciencies have been reported
in neonates suﬀering from acute illness [9]. In contrast
to the breast milk containing glutamine adequate to inﬂu-
ence gastrointestinal development and modulate immune,
metabolic, andinﬂammatoryresponsesofthenewborn[10],
standard infant formulas are low, and parenteral amino acid
formulas are free of glutamine [11].
One described hypothesis for the release of glutamine
following stress is that it provides a vital fuel source for
rapidly dividing cells such as those of the immune system
[12] and gastrointestinal tract [13], reticulocytes [14], and
ﬁbroblasts [15]; it is a precursor for nucleic acid synthesis,
hexosamines,andnucleotides[12];thenitricoxideprecursor
arginine [16]; the major antioxidant-glutathione [17]; a key
precursor for acid-base homeostasis in the kidney [18]. In2 Clinical and Developmental Immunology
addition to its role as a gluconeogenic substrate in the
intestine, liver, and kidney [19, 20], glutamine is involved
in nitrogen transport from muscle to gut, kidney, and liver
[21] and the regulation of acid-base homeostasis by renal
regulationofinterorganglutamineﬂowinmetabolicacidosis
[22].
Glutamine may have beneﬁts during experimental
neonatal endotoxemia and in premature infants of very low
birth weight (VLBW), who are highly stressed and have low
energy and protein reserves [23]. Undergoing rapid growth,
preterm infants are most likely to be exposed to severe
glutamine deﬁciency (conditionally essential) more than
term infants [7]. Glutamine supplementation may also be
beneﬁcial for critical childhood conditions including cancer,
severe burns/trauma, as well as gastrointestinal disease and
malnutrition. Its eﬀects on pediatric systemic inﬂammation
or acute illness, however, are unknown since less data is
available on the eﬀects of supplemental glutamine in infants
and critically ill children. The administration of glutamine
nutrient-enriched diets did not change the mortality of the
critically ill or surgical adult patients, but infection compli-
cations in the critically ill patients, particularly the surgical
population, were reduced [24].There is little information on
the role of pharmaconutrients in neonatal endotoxemia, or
whether glutamine supplementation is beneﬁcial in preterm
babies or critically ill children. The purpose of this paper
was (a) to discuss the recent research-based evidence of
the glutamine role in sepsis, which best of all describes a
critical illness situation, and (b) to present the heterogeneity
and diﬀerences of methods and results of randomized
experimental and clinical studies of dietary glutamine in
early life: from VLBW and preterm infants to children and
up to adults.
2.The GlutamineRole inSepsis
Immunopathology andMetabolism
Sepsis is the systemic inﬂammatory response associated with
an infectious insult. It is the leading cause of death in
critically ill patients, and the predominant cause of multiple
organ dysfunctions that is known to develop in response
to infection. Sepsis occurs in over 750,000 patients per
year in the United States and exhibits a mortality rate of
28% to 48% depending on the age of the patient [25].
Nosocomial infection/sepsis occurs in more than 40% of
children requiring long-term intensive care [26]. Potential
antiendotoxin strategies may have the potential to reduce
severity of illness and length of Pediatric Intensive Care Unit
(PICU) stay in critically ill children [27]. In very preterm
(<32 weeks of gestation) and/or very low birth weight
(VLBW < 1500g birth weight) infants, serious neonatal
infections are among the main causes of poor developmental
outcomes later in childhood. Implementation of an emer-
gency department septic shock protocol and care guideline
improved compliance in delivery of rapid, aggressive ﬂuid
resuscitation and early antibiotic and oxygen administration
andwasassociatedwithdecreasedlengthofstay[28].Despite
signiﬁcant advances in critical care, there is still no eﬃcient
causal therapy applicable to patients indicating the need
to further elucidate the molecular pathways leading to the
immunopathology of sepsis [29]. In addition, host genetic
variability in the regulatory and coding regions of genes for
components of the innate immune system may inﬂuence the
susceptibility to and/or outcome from sepsis [30].
Speciﬁc nutrients known as pharmaconutrients have
demonstrated an ability to modulate the immunologic and
inﬂammatory responses in clinical and laboratory studies.
Among these substrates, arginine, glutamine, n-3 fatty
acids, and nucleotides are the most relevant and exhibit
the greatest immune-modulatory action [31]. Although
the mechanisms of how pharmaconutrients beneﬁt criti-
cally ill patients have not been established, experimental
work has shown that glutamine regulates the expression
of many genes related to signal transduction, antioxidant
capacity, immune and metabolic function [32], protein
synthesis, and degradation and activates intracellular sig-
nalling pathways [33]. Thus, the eﬀectiveness of glutamine
in preventing liver damage in neonatal sepsis appears to
be mediated via glutathione synthesis [34]. In addition,
glutamine could improve insulin sensitivity and glucose
disposal in patients suﬀering from critical illness, a condition
frequently associated with insulin resistance and subsequent
hyperglycemia [35]. By being involved in the biosynthesis
of hexosamines, glutamine maintains gut wall integrity via
surface mucin and glycoprotein-forming intracellular tight
junctions and protects against bacterial translocation [36].
When hepatocytes from endotoxaemic rats were incubated
with glutamine, there was a restoration of mitochondrial
structure and metabolism. In vivo, intraperitoneal injec-
tion of glutamine into endotoxic suckling rats partially
reversed hypometabolism, markedly reduced the incidence
of hypothermia, and improved clinical status [37].
Activation of NF-κB is dependent on the phosphoryla-
tion and degradation of IKB-α, an endogenous inhibitory
molecule that binds to NF-κB in the cytoplasm [38]. In
an experimental study glutamine suppressed NF-κBt r a n -
scriptional activation and translocation to the nucleus and
signiﬁcantly inhibited IKB-α phosphorylation and degra-
dation in lung cytosolic tissue [39]. Similarly, glutamine
administration attenuated the peak in IL-18 release at 12–
24h and maintained IL-18 levels at a consistently low
level throughout the initial 24-h period after cecal ligation
and puncture (CLP) in rats [39]. Thus, glutamine’s eﬀect
on IL-18 expression may be an additional mechanism by
which glutamine improves survival and decreases end-organ
dysfunction following polymicrobial sepsis.
3. The Secretsof Molecular Chaperones
The heat shock response is a highly conserved cellular mech-
anism that protects against injury and environmental
stresses. Intracellular heat shock proteins (hsps) function as
molecular chaperones governing protein assembly, folding,
ortransportandasanti-apoptoticregulatorsofcellsignalling
pathways leading to cell death [40]. In addition, hsp peptides
promote the production of anti-inﬂammatory cytokines,Clinical and Developmental Immunology 3
indicating immune-regulatory potential of hsps [40]. Of
particular importance is the expression of members of the
70-kd hsp70 family. Experimental results indicate that the
expression of inducible hsp70 is vital to protect against the
proinﬂammatory response and lung injury associated with
sepsis. Induction of hsp60 has also been demonstrated in
cerebral ischemia models, possibly reﬂecting mitochondrial
stress and occurred early after the injury [41]. Sepsis, endo-
toxin tolerance, and heat shock all display downregulation
of innate immunity, sharing a common immune suppressive
eﬀect, possibly through HS factor 1 (HSF-1)-mediated
competitive inhibition of NF-κB binding [42]. Heat shock
protein 70 plasmid-transfected cells had increased hsp70
expression and demonstrated decreased nitric oxide (NO)
release and inducible NO synthase messenger RNA expres-
sion in response to endotoxin compared with wild-type and
empty plasmid-transfected cells [42]. Cell cycle components,
regulatory proteins, and proteins in the mitogenic signal
cascade may be protected by hsp70 during periods of stress
[43].
Experimental evidence suggests that hsp70 expression
is required for glutamine’s protection against tissue injury
and for attenuation of NF-κB activation and proinﬂam-
matory cytokine release [44]. In the human gut, enteral
glutamine may attenuate ubiquitin-dependent proteolysis
as demonstrated by decreased ubiquitin RNA [45], and
in lung and muscle, it can regulate glutamine synthetase
protein degradation by facilitating its degradation by the 26S
proteosome [46]. It was shown that absence of hsp70 alone
can signiﬁcantly increase ARDS, activation of NF-κB, and
inﬂammatorycytokineresponsewhereasthespeciﬁcabsence
of hsp70.1/3 gene expression can lead to increased mortality
after septic insult [47]. The survival-promoting eﬀects of
hsp70 could also be attributed in part to the suppression
of apoptosis, since reduced hsp expression in glutamine-
deprived cells together with their impaired antioxidant
capacity may make them more susceptible to apoptosis [48].
4.GlutamineIsaProchaperone
A signiﬁcant body of preexisting literature has hypothesized
a relationship between hsp70 expression and glutamine’s
protection in both in vitro and in vivo settings [39–44]. Glu-
tamine has been shown to induce heat shock protein expres-
sion and to attenuate lipopolysaccharide (LPS)-mediated
cardiovascular dysfunction. The molecular mechanism of
glutamine-induced hsp70 expression appears to be mediated
via enhancement of O-linked β-N-acetylglucosamine (O-
GlcNAc) modiﬁcation and subsequently to increase levels
of endonuclear HSF-1 expression and HSF-1 transcription
activity [49]. The molecular mechanism of glutamine-
mediated hsp70 expression appears to be dependent on O-
GlcNAc pathway activation and subsequent O-glycosylation
andphosphorylationofkeytranscriptionfactorsrequiredfor
hsp70 induction [50]. It has been demonstrated that a single
dose of intravenous glutamine enhances phosphorylation of
nuclear HSF-1, which is a vital step in its transcriptional
activation [51], causing a rapid and signiﬁcant increase in
hsp25 and hsp 72 expression in multiple organs of the
unstressed Sprague-Dawley rat [52].
Pioneer studies showed that glutamine supplementation
could attenuate lethal heat and oxidant injury and increase
hsp72 expression in intestinal epithelial cells (IEC-6 cells)
[53–55]. The eﬀect of glutamine in delaying spontaneous
apoptosis in neutrophils and protecting activated T cells
may be mediated by upregulating glutathione [56]a n dB c l -
2 expression and inhibiting Fas [57]. Glutamine eﬀectively
improved vascular reactivity by inducing the expression of
hsp70, reducing inﬂammatory cytokine release and peroxide
biosynthesis in LPS shock rats [58]. In a recent study,
septic mice with glutamine administration showed less
severe damage to the kidneys and exhibited decreased high
mobility group box protein-1 (HMGB-1), toll-like receptor-
4, receptor of advanced glycation end-products (RAGE),
and reduced nitrotyrosine levels in kidney tissues [59]. In
glutamine-treated rats, lung hsp70 and HSF-1-p expressions
were enhanced, lung HMGB-1 expression and NF-κBD N A -
binding activity were suppressed, ARDS was attenuated and
survival improved [60]. Similarly, by inducing hsp70 in an
experimental model, glutamine was also shown to attenuate
LPS-induced cardiomyocyte damage [49].
Marked attenuation of tissue metabolic dysfunction
was observed after glutamine administration as measured
by lung tissue adenosine 5 -triphosphate/adenosine 5 -
diphosphate ratio and the oxidized form of nicotinamide
adenine dinucleotide [61]. Furthermore, the ATPase cycle of
the chaperone hsp70 is regulated by co-chaperones. Hsp40
related proteins stimulate ATP hydrolysis by hsp70, whereas
hsp25, which is known to be a vital protective protein via
interaction with the cytoskeleton, may play an important
role in glutamine’s cellular protection [40]. It was shown
that glutamine could protect intestinal epithelial cells in
a dose-dependent fashion against heat stress and oxidant
injury [53], decrease lung injury [61], and enhance hsp
expression after endotoxin shock thus, improving survival
[52]. It has also been shown that hsp70 levels increase in
the myocardium of rats in experimental diabetes mellitus as
a protective mechanism and may be further increased with
parenteral administration of glutamine [62]. A randomized
trial in adult patients with full-thickness burns showed for
theﬁrsttimethatorallyadministeredglutaminecanenhance
tissue hsp70 expression [63] and improve survival following
lethal hyperthermia injury [64]. It was hypothesized that
glutamine may act as a HSF-1 activator and increase the
entire family of hsps after stress or injury since in HSF-1
knockout mouse ﬁbroblasts, glutamine’s ability to generate
an hsp response is lost and the protection conferred by
glutamine is also completely abrogated [51].
5.Ornithine:A GlutamineAlternative
Glutamine is a substrate for polyamine synthesis and
stimulates the activity of ornithine decarboxylase (ODC), a
key enzyme for polyamine synthesis, in intestinal epithelial
cells. In a recent experimental work, polyamines (putrescine,
spermidine, or spermine) and their precursor ornithine4 Clinical and Developmental Immunology
mediated the induction of hsp expression in IEC-18 rat
intestinal epithelial cells [65]. As previously observed, glu-
tamine was required for heat stress-induction of hsp70 and
hsp25, although it had little eﬀect under basal conditions.
Under conditions of glutamine depletion, supplementation
of ornithine, or polyamines restored the heat-induced
expression of hsp70 and hsp25. In the same study, when
ODC was inhibited by α-diﬂuoromethylornithine (DFMO),
an irreversible ODC inhibitor, the heat stress-induction
of hsp70 and hsp25 was signiﬁcantly decreased even in
the presence of glutamine [65]. Ornithine, polyamines,
and DFMO did not modify the nuclear localization of
HSF-1. However, DFMO dramatically reduced glutamine-
dependent HSF-1 binding to an oligonucleotide with heat
shock elements (HSE) which was increased by glutamine. In
addition, exogenous polyamines recovered the DNA binding
activity. These results indicated that polyamines play a
critical role in the glutamine-dependent induction of the
intestinal epithelial heat shock response through facilitation
of HSF-1 binding to HSE [65].
6. FactorsInﬂuencingGlutamine
ProtectiveRole inSepsis
Recent work demonstrated that febrile-range temperatures
achieved during sepsis and noninfectious SIRS correlated
with detectable changes in stress gene expression in vivo
(whole blood messenger RNA), thereby suggesting that
fever can activate hsp70 gene expression and modify innate
immune responses [66]. In addition, analysis of septic
patients according to survival outcome indicated that hsp70
serum levels were modulated according to the patient
oxidant status [67]. Unexpectedly, hsp70 was shown to be a
key determinant of mortality in aged, but not young hosts in
sepsis. It might be concluded therefore, that hsp70 may play
a protective role in an age-dependent response to sepsis by
preventing excessive gut apoptosis and both pulmonary and
systemic inﬂammation [68].
Critically ill patients display variable physiologic re-
sponses when stressed; gene association studies have recently
been employed to explain this variability. Genetic variants
of hsp70 have also been associated with the development
of septic shock in patients [69, 70]. The speciﬁc absence of
hsp70.1/3 gene expression can lead to increased mortality
after septic insult [47].
Drug interactions were also shown to either suppress
hsp protective eﬀects exacerbating therefore drug-induced
side eﬀects or to induce hsp beneﬁcial eﬀects by suppressing
drug-induced exacerbations. Thus, it was recently shown
that bleomycin-induced pulmonary ﬁbrosis is mediated by
suppression of pulmonary expression of hsp70 whereas an
inducer of hsp70 expression, such as geranylgeranylacetone,
may be therapeutically beneﬁcial for the treatment of
geﬁtinib-induced pulmonary ﬁbrosis [95].
7.RandomizedAdult Studies
Despite the enthusiastic experimental results, suggesting
ab e n e ﬁ c i a le ﬀect for the immune-enhancing glutamine,
systematic reviews and meta-analyses of randomized studies
failed to show any deﬁnite beneﬁt of pharmacononutrition
in the critically ill adult [96]. Most of the randomized
studies have been largely performed in surgical patients [97],
and only a few in trauma patients receiving glutamine-
supplemented enteral nutrition [98] or septic patients on
enteral immunonutrition [99].
In a multicenter, prospective, double-blind, randomized
trial total parenteral nutrition (PN) supplemented with
alanine-glutamine in intensive care unit patients was asso-
ciated with a reduced rate of infectious complications and
better glycemic control [100]. In another recent multicenter
randomized, double blinded, factorial, controlled trial, 502
intensive care patients requiring PN were supported with
parenteral glutamine (20.2g/day) or selenium (500μg/day)
or both, for up to seven days [101]. The primary (intention
to treat) analysis showed no eﬀect on new infections or
on mortality when PN was supplemented with glutamine
or selenium. Also, length of stay, days of antibiotic use,
and modiﬁed SOFA score were not signiﬁcantly aﬀected by
selenium or glutamine supplementation.
8.Randomized ExperimentalandClinical
Studiesof GlutamineSupplementation
in Early Life
The search methods for identiﬁcation of studies consisted of
searches of PubMed database using the search terms: “glu-
tamine” and “critical illness,” or “sepsis,” or “endotoxemia.”
The search output was limited with the search ﬁlter for ages:
pups, infants, and children. References in selected studies
were examined also. The title and abstract of all studies
identiﬁed by the above search strategy were screened and
the full text for all potentially relevant studies published
in English was obtained. The full text of any potentially
relevant studies was assessed by the two authors (EB, GB).
The same authors extracted data from the published studies.
Study populations, main methodological data and results on
outcome are presented in Tables 1, 2,a n d3.
8.1. Glutamine Supplementation in Animal Pups. Using light
and transmission electron microscopy in artiﬁcially reared
rat pups the greatest blunting of villus height in the ileum
and the lowest number of villi per unit length of bowel
were in the animals that were treated with inhibition of
glutamine and not provided with dietary glutamine [75].
Transmission electron microscopy demonstrated break-
down of the epithelial junctions in the glutamine-deprived
and glutamine synthetase-inhibited intestines. Glutamine-
deprived animals also displayed sloughing of microvilli,
decreased actin cores, and degeneration of the terminal
web [75]. In an experimental controlled study, glutamine
and leucine both caused nutrient-induced thermogenesis in
control animals and restored oxygen consumption (VO2,
mL/kg/h) of endotoxic suckling rats [71]. Glutamine addi-
tionally increased rectal temperature, reduced incidence of
hypothermia, and improved clinical signs. Undernourished
pups/dam supplemented with glutamine with or withoutClinical and Developmental Immunology 5
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zinc showed increased CA1 layer volume and hippocam-
pal gamma-aminobutyric acid and synaptophysin levels
as compared with the other groups, consistent with the
trend toward increased number of neurons and protection
against malnutrition-induced brain developmental impair-
ments [72]. Also, glutamine supplementation during brain
development facilitated cortical spreading depression propa-
gation, as judged by the higher cortical spreading depression
velocities, recorded on 2 cortical parietal points of the right
hemisphere, an eﬀect not abolished by malnutrition [73].
Importantly, when injected intraperitoneally in eleven-day
rat pups, glutamine partially prevented the sepsis-induced
fallinplasmaglutaminelevelsandreducedtheconcentration
of both proinﬂammatory and anti-inﬂammatory cytokines
[74].
8.2. Parenteral Glutamine in Extremely Low Birth Weight
(ELBW) and Preterm Infants. Glutamine appears to be safe
for use in premature infants and seems to be conditionally
essential in premature infants with extremely low birth
weights [82]. In ELBW infants, parenteral glutamine supple-
mentation could increase plasma glutamine concentrations
without apparent biochemical risk [83]. When supple-
mented PN for more than 2 weeks, glutamine shortened
days on PN and length of stay in hospital, and decreased
hospital acquired infection episodes in premature infants
[81]. Although parenteral glutamine failed to enhance rates
of protein synthesis, it was assumed that it may have an acute
protein-sparing eﬀect, as it suppressed leucine oxidation and
protein breakdown, in parenterally fed very low birth weight
infants [80]. Thus, parenteral glutamine supplementation
was shown to be associated with lower whole-body protein
breakdown and protein accretion in selected populations of
LBW infants [77] and to improve hepatic tolerance in VLBW
infants,suggestingahepato-protectiveeﬀect[84].Inanother
randomized study, although parenteral glutamine appeared
to be well tolerated and safe in the ill preterm neonate,
able to reduce the time to achieving enteral nutrition, it did
not reduce the episodes of culture-positive sepsis or age at
discharge [78].
In a large multicenter, randomized, double-masked, clin-
ical trial in ELBW infants, the safety and eﬃcacy of early
PN supplemented with glutamine in decreasing the risk of
death or late-onset sepsis were assessed; infants 401 to 1000g
were randomized within 72 hours of birth to receive either
TrophAmine (control) or an isonitrogenous study amino
acid solution with 20% glutamine whenever they received
PN up to 120 days of age, death, or discharge from the
hospital [76]. Of the 721 infants assigned to glutamine
supplementation, 370 (51%) died or developed late-onset
sepsis, as compared with 343 of the 712 control infants
(48%). Also glutamine had no eﬀect on tolerance of enteral
feeds, necrotizing enterocolitis, or growth. No signiﬁcant
adverse events were observed with glutamine supplemen-
tation. Accordingly, although no harm was demonstrated,
parenteralglutaminesupplementationasstudiedinthislarge
study could not be recommended in ELBW infants [76].
In a double-blind, randomized trial, short-term glutamine-
supplementation (0.4g/kg/day) of PN did not show any
beneﬁt on intestinal permeability in newborns and infants
after major digestive-tract surgery [79]. Similarly, in a recent
randomized clinical trial of glutamine-supplemented versus
standard PN, glutamine supplementation did not reduce the
incidence of sepsis in surgical infants with gastrointestinal
disease [85]. Thus, using the Cochrane Central Register of
Controlled Trials (The Cochrane Library, 2011, Issue 4),
MEDLINE, EMBASE and CINAHL (to November 2011),
conference proceedings and previous reviews, it has been
recentlyconcludedthattheavailabletrialdatadonotprovide
evidence that glutamine supplementation confers important
beneﬁts for preterm infants [102].
8.3. Enteral Glutamine in ELBW and Preterm Infants.
Double-blind randomized trials in VLBW infants did not
showthatenteralglutaminesupplementationdecreasesmor-
bidity or mortality [87, 103]. Blinded, randomized studies
providedevidenceforabluntingoftheinﬂammatoryprocess
[86] and lower sepsis rates in VLBW infants receiving enteral
glutamine supplementation [88]. In contrast to reports
showing better tolerance to enteral feedings in glutamine-
enriched enteral nutrition in VLBW infants [87], other
studies did not ﬁnd any improvement of the median days
to reach full enteral feeds [86, 88]. In addition, despite a
decreased infectious morbidity, glutamine supplementation
in VLBW infants was not associated with alterations in the
prevalence of biﬁdobacteria, lactobacilli, E. coli [89] and did
not enhance the postnatal decrease in intestinal permeability
in this population [90]. Importantly, examining the eﬀect of
enteral glutamine on whole-body kinetics of glutamine in
growing preterm infants, enterally administered glutamine
was shown to be entirely metabolized in the gut and to have
no detectable eﬀect on whole-body protein and nitrogen
kinetics [104]. Studied by dual tracer cross-over techniques,
dietary glutamine was shown to be used to a great extent by
the splanchnic tissues in preterm infants, its carbon skeleton
having an important role as fuel source [105]. Similarly
no diﬀerences between groups for plasma concentrations
of glutamine, glutamate, other amino acids, glucose, or
ammonia were shown during the enteral supplementation of
glutamine [106, 107].
Followup of all surviving VLBW infants having received
enteral preterm formula or breast milk supplemented with
glutamine showed a lower risk of atopic dermatitis but no
diﬀerences in incidence of bronchial hyperactivity, infec-
tions of upper respiratory, lower respiratory, urinary, or
gastrointestinal tracts [108, 109], of intestinal microbiota,
neurodevelopmental impairment or cerebral palsy [110]. No
diﬀerence was also detected among randomized groups in
intestinal (faecal) microbiota at age 1 year as analyzed by
ﬂuorescent in situ hybridization [111] or in TH1 and TH2
cytokine proﬁles either during the days of supplementation
[91] or at 1 year of age following in vitro whole blood
stimulation [112]. Importantly, glutamine-enriched enteral
nutrition in VLBW infants had neither beneﬁcial nor detri-
mental eﬀects on long-term cognitive, motor, and behavioral
outcomes of very preterm and/or VLBW children at school
age, although visuomotor abilities were poorer in children
that received glutamine [113].12 Clinical and Developmental Immunology
8.4. Eﬀect of Glutamine Supplementation on Critically Ill Chil-
dren. In a multicenter randomized, double-blinded, com-
parative eﬀectiveness trial, zinc, selenium, glutamine, and
intravenous metoclopramide conferred no advantage in the
immune-competent population of children requiring long-
term intensive care compared with whey protein supple-
mentation [26]. Further evaluation of these constituents’
supplementation was thought to be warranted only in the
immune-compromised long-term pediatric intensive care
unit patient.
Inablinded,prospective,randomized,controlledclinical
trial in critically ill children given an immune-enhancing
formula supplemented with glutamine, a favorable eﬀect on
nutritional indices and antioxidant catalysts was reported,
but none on outcome hard endpoints [92]. Also, although
it posed a higher metabolic burden to the patient, it showed
a trend to improve colonization and infection rates; diarrhea
in the immunonutrition and gastric distention in the control
groupwerethemostfrequentlyrecordedcomplications[92].
In another single-center, randomized, blinded controlled
trial in children with septic shock a signiﬁcant decrease
in IL-6 levels was recorded after 5 days of early enteral
feeding using the same immune-enhancing formula [93].
The variation in cytokines was independently correlated
only to PRISM, but mortality and other pediatric intensive
care unit outcome hard endpoints did not diﬀer between
the two groups. Similarly, in another randomized, blinded,
controlled study in children with severe head injury, using
masked isocaloric formulae, immunonutrition improved
nitrogen balance and decreased interleukin-8 and gastric
colonization but was not associated with additional clinical
advantage over the one demonstrated by conventional early
enteral nutrition [94]. In two randomized studies in trauma
patients (children and adults) no signiﬁcant diﬀerences were
also recorded in mortality, LOS, lung infection or immuno-
logic or biochemical parameters between the glutamine
supplemented groups (enteral or parenteral) and controls
[114, 115].
9. Concluding Remarks
Given the encouraging experimental results, the absence
of glutamine-related adverse eﬀects, and the immune cells
need for glutamine to grow and multiply, it has long been
hypothesized that high risk patients could beneﬁt from
the use of this highly promising pharmaconutrient [12];
furthermore, combining glutamine with antioxidants and
other selective pharmaconutrients, might exert an extra-
synergic immune-enhancing eﬀect. Thus, parenteral glu-
tamine supplementation for 7 days increased total plasma
glutathionelevelsinadulttraumapatientsreceivingstandard
enteralnutrition[116].Inanotherstudy,however,glutamine
administration by enteralor parenteralroutesdid not appear
to aﬀect antioxidant capacity or oxidative stress markers
compared to unsupplemented adult ICU patients [117].
Studies evaluating the eﬀect of speciﬁc pharmaconutri-
ents in premature infants and critically ill children are scarce
and are insuﬃc i e n tt oa l l o wr e c o m m e n d a t i o n st ob em a d e .
Recent evidence from studies in various pediatric diseases
and in premature newborns remains inconsistent, partly
because of the diﬀerent eﬀects of enteral and parenteral glu-
tamine supplementation, ineﬃc i e n tt r e a t m e n td o s e s[ 118],
co-administered multi-immune-enhancing constituents or
more or less amino-acids, heterogeneity, timing, dosing
regimens, and other [119]. In our meta-analysis, none of
the randomized studies in early life showed any eﬀect in
mortality, one in the length of stay, and only a few showed
some eﬀect on inﬂammatory response, organ function and a
trend for infection control. Thus, although apparently safe
in ELBW premature infants and in critically ill children,
blinded controlled randomized studies in these populations
concluded that glutamine supplementation does not reduce
mortality or late onset sepsis, and its routine use cannot be
recommended for the immune-competent patients.
Once again, laboratory research preliminary beneﬁcial
eﬀectsfailedtobereproducedinclinicalrandomized(and/or
blinded and masked) studies. The lack of beneﬁcial eﬀect of
glutamine supplementation in sepsis might be explained by
any of the factors inﬂuencing glutamine protective role as
described above. Various factors during the clinical course
might have also inﬂuenced results of those studies. In
addition, by using isonitrogenous controls (to ensure the
speciﬁc eﬀect of glutamine), the overall amino acid intake
may have been inadequate in the glutamine group, as a
consequence of the substitution of 20% of the standard
amino acids with glutamine. Although adding more amino
acidstothecontrolgroupsmighthavepreventedtheremoval
of amino acids from the glutamine supplement, the isoni-
trogenous control groups would have then received more
amino acid/nitrogen than the recommended allowances.
On the other hand, enteral supplementation of glutamine
seems to be locally used by the intestine but may not help
entering the systemic circulation to enhance the immune
response. All these diﬀerent research methods along with the
use of diﬀerent feeding guidelines for the introduction or
withholding parenteral and enteral feeds among institutions
make comparisons between studies diﬃcult [120]. Further
molecular and biochemical data is needed along with large
randomized controlled trials in select populations of sick
children, such as immune-compromised, who may eventu-
ally beneﬁt from supplemental glutamine.
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